Friedreich's Ataxia (FRDA) Therapeutics - Pipeline Analysis 2017

  • ID: 4426642
  • Report
  • 92 pages
  • P&S Market Research
1 of 3
Friedreich's ataxia therapeutics pipeline in 2017

The study analyzed that the Friedreich's ataxia therapeutics pipeline comprises approximately 17 drug candidates in different stages of development. Friedreich’s ataxia is an autosomal recessive inherited genetic disorder that progressively damages the nervous system. Its initial symptoms include ataxia, impaired muscle coordination and impaired speech. This results in development of dysarthria, scoliosis, heart diseases and diabetes, but does not affect cognitive function.

Insights on Pipeline Segments

According to the research findings, most of the drug candidates in Friedreich's ataxia therapeutics pipeline are being developed to be administered by oral route.

Various Grants from Friedreich's Ataxia Research Alliance (FARA)

Catabasis Pharmaceuticals, Inc. received Kyle Bryant Translational Research award from the FARA for the evaluation of their drug candidate, which is being developed for the treatment of Friedreich’s ataxia.

Drugs are being developed using natural sources in the Friedreich's Ataxia (FRDA) Therapeutics Pipeline

The research also found that various companies are in the process of developing the drug candidates using natural sources for the treatment of Friedreich's ataxia therapeutics pipeline. Cardero Therapeutics, Inc. is in the process of developing a drug candidate as a sterol using natural source, for the treatment of Friedreich's ataxia.

Some of the key players developing drugs for the treatment of Friedreich's ataxia include Cardero Therapeutics, Inc., Edison Pharmaceuticals, Inc., Retrotope, Inc. and others.

Friedreich's Ataxia (FRDA) Therapeutics Pipeline Analysis
  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company
Note: Product cover images may vary from those shown
2 of 3
1. Research Background
1.1. Research Objectives
1.2. Definition
1.3. Research Scope
1.3.1. Pipeline Analysis by Phase
1.3.2. Pipeline Analysis by Route of Administration
1.3.3. Pipeline Analysis by Molecule Type
1.4. Key Stakeholders

2. Research Methodology
2.1. Secondary Research
2.2. Primary Research
2.2.1. Breakdown of Primary Research Respondents By industry participants By company type

3. Executive Summary

4. Pipeline Outlook
4.1. Friedreich’s Ataxia Therapeutics Overview
4.1.1. Signs and Symptoms
4.1.2. Pathophysiology
4.1.3. Diagnosis
4.1.4. Treatment
4.1.5. Epidemiology
4.2. Key Drivers
4.3. Key Barriers
4.4. Friedreich’s Ataxia Therapeutics Pipeline Analysis
4.4.1. Pipeline Analysis by Phase
4.4.2. Pipeline Analysis by Molecule Type
4.4.3. Pipeline Analysis by Route of Administration
4.4.4. Pipeline Analysis by Company

5. Friedreich’s Ataxia Therapeutics Pipeline Analysis by Phase (2017)
5.1. Pre-registration/Registration: Drug Profiles
5.1.1. Pre-Clinical Studies
5.1.2. Clinical Trials
5.1.3. Clinical Results
5.1.4. Strategic Developments
5.1.5. Designations
5.1.6. Grants
5.1.7. Patents
5.1.8. Technology
5.2. Phase III: Drug Profiles
5.2.1. Pre-Clinical Studies
5.2.2. Clinical Trial
5.2.3. Clinical Results
5.2.4. Strategic Developments
5.2.5. Designations
5.2.6. Grants
5.2.7. Patents
5.2.8. Technology
5.3. Phase II: Drug Profiles
5.3.1. Pre-Clinical Studies
5.3.2. Clinical Trials
5.3.3. Clinical Results
5.3.4. Strategic Developments
5.3.5. Designations
5.3.6. Grants
5.3.7. Patents
5.3.8. Technology
5.4. Phase I: Drug Profiles
5.4.1. Pre-Clinical Studies
5.4.2. Clinical Trials
5.4.3. Clinical Results
5.4.4. Strategic Developments
5.4.5. Designations
5.4.6. Grants
5.4.7. Patents
5.4.8. Technology
5.5. Pre-Clinical: Drug Profiles
5.5.1. Pre-Clinical Studies
5.5.2. Strategic Developments
5.5.3. Designations
5.5.4. Grants
5.5.5. Patents
5.5.6. Technolog
5.6. Discovery: Drug Profiles
5.6.1. Strategic Developments
5.6.2. Designations
5.6.3. Grants
5.6.4. Patents
5.6.5. Technology
5.7. Inactive: Drug Profiles
5.7.1. Pre-Clinical Studies
5.7.2. Clinical Trials
5.7.3. Clinical Results
5.7.4. Strategic Developments
5.7.5. Designations
5.7.6. Grants
5.7.7. Patents
5.7.8. Technology
5.8. Discontinued: Drug Profiles
5.8.1. Pre-Clinical Studies
5.8.2. Clinical Trials
5.8.3. Clinical Results
5.8.4. Strategic Developments
5.8.5. Designations
5.8.6. Grants
5.8.7. Patents
5.8.8. Technology

6. Clinical Trials Analysis
6.1. Clinical Trials by Region
6.2. Clinical Trials by Trial Status

7. Competitive Landscape Analysis
7.1. Key Players Benchmarking
7.2. SWOT Analysis

8. Company Profiles
8.1 Business Overview
8.2 Product and Service Offerings

9. Appendix
9.1 Abbreviations

Note: Certain sections of the above table of contents would vary according to the availability of information.
Note: Product cover images may vary from those shown
3 of 3


4 of 3
Note: Product cover images may vary from those shown